Abstract：
UNASSIGNED: Dehiscence and infection of hard-to-heal surgical wounds results in an increased risk of complications and mortality. A hard-to-heal surgical wound will present decreased levels of growth factors along with increased levels of debris and matrix metalloproteinases, resulting in the destruction of the extracellular matrix (ECM). ActiGraft (RedDress Ltd., Israel) is an autologous whole blood clot treatment, created at a point of care, to promote wound healing. We hereby present the efficacy of ActiGraft in a case series of hard-to-heal surgical wounds.
UNASSIGNED: A registry study of patients with surgical wounds was conducted in private clinics and hospitals across the US and Israel (NCT04699305). Autologous whole blood clot was created at point of care using the patient\'s own blood.
UNASSIGNED: A total of 14 patients took part in the study. Autologous whole blood clot treatment resulted in a mean percent wound area reduction of 72.33% at four weeks, with 33.33% of wounds achieving complete closure by week 4. At week 12, 78.54% of the wounds achieved complete closure.
UNASSIGNED: Surgical wounds in patients with comorbidities may fail to initiate the natural wound healing mechanism which in turn may cause deterioration of the wound into a hard-to-heal stage. In this case series, autologous whole blood clot treatment was able to restore wound healing, avoiding the risk of infection and amputation of an affected limb. The properties of autologous whole blood clot as an ECM reduce the risk of infection, causing the wound to progress from the inflammatory phase to the proliferative phase. Autologous whole blood clot treatment in hard-to-heal surgical wounds was found to be an effective approach, reducing the risk of infection and promoting cell granulation, resulting in wound closure.
UNASSIGNED: A registry study of patients with surgical wounds was conducted in private clinics and hospitals across the US and Israel (NCT04699305). Autologous whole blood clot was created at point of care using the patient\'s own blood.
UNASSIGNED: A total of 14 patients took part in the study. Autologous whole blood clot treatment resulted in a mean percent wound area reduction of 72.33% at four weeks, with 33.33% of wounds achieving complete closure by week 4. At week 12, 78.54% of the wounds achieved complete closure.
UNASSIGNED: Surgical wounds in patients with comorbidities may fail to initiate the natural wound healing mechanism which in turn may cause deterioration of the wound into a hard-to-heal stage. In this case series, autologous whole blood clot treatment was able to restore wound healing, avoiding the risk of infection and amputation of an affected limb. The properties of autologous whole blood clot as an ECM reduce the risk of infection, causing the wound to progress from the inflammatory phase to the proliferative phase. Autologous whole blood clot treatment in hard-to-heal surgical wounds was found to be an effective approach, reducing the risk of infection and promoting cell granulation, resulting in wound closure.
摘要：
未经证实：难以愈合的手术伤口的裂开和感染导致并发症和死亡的风险增加。难以愈合的手术伤口将呈现降低的生长因子水平以及增加的碎片和基质金属蛋白酶水平。导致细胞外基质（ECM）的破坏。Actigraft（RedDressLtd.，以色列）是一种自体全血凝块治疗，在护理点创建，促进伤口愈合。我们在此介绍了在一系列难以愈合的手术伤口中，ActiGraft的功效。
UNASSIGNED：在美国和以色列的私人诊所和医院进行了一项手术伤口患者的注册研究（NCT04699305）。使用患者自身的血液在护理点产生自体全血凝块。
未经授权：共有14名患者参加了这项研究。自体全血块治疗在四周时导致平均伤口面积减少百分比为72.33％，33.33%的伤口在第4周时完全闭合。在第12周,78.54%的伤口实现完全闭合。
未经证实：合并症患者的手术伤口可能无法启动自然伤口愈合机制，进而可能导致伤口恶化至难以愈合的阶段。在这个系列中,自体全血凝块治疗能够恢复伤口愈合，避免感染和截肢的风险。自体全血凝块作为ECM的特性降低了感染的风险，导致伤口从炎症阶段进展到增殖阶段。自体全血块治疗难以愈合的手术伤口被发现是一种有效的方法，降低感染风险和促进细胞肉芽，导致伤口闭合。
UNASSIGNED：在美国和以色列的私人诊所和医院进行了一项手术伤口患者的注册研究（NCT04699305）。使用患者自身的血液在护理点产生自体全血凝块。
未经授权：共有14名患者参加了这项研究。自体全血块治疗在四周时导致平均伤口面积减少百分比为72.33％，33.33%的伤口在第4周时完全闭合。在第12周,78.54%的伤口实现完全闭合。
未经证实：合并症患者的手术伤口可能无法启动自然伤口愈合机制，进而可能导致伤口恶化至难以愈合的阶段。在这个系列中,自体全血凝块治疗能够恢复伤口愈合，避免感染和截肢的风险。自体全血凝块作为ECM的特性降低了感染的风险，导致伤口从炎症阶段进展到增殖阶段。自体全血块治疗难以愈合的手术伤口被发现是一种有效的方法，降低感染风险和促进细胞肉芽，导致伤口闭合。
